PDC*line Pharma
France - La TronchePharmaceutical
Focus: PDC*line Pharma is a French biotech company developing a novel class of off-the-shelf cancer immunotherapies based on plasmacytoid dendritic cell (pDC) technology pre-loaded with peptides. The company is in early-stage development with a single Phase 1/2 program in non-small cell lung cancer.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About PDC*line Pharma
AI assessmentNot HiringNo open roles listed right now. Follow PDC*line Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
PDC*lung01
Non Small Cell Lung CancerClinical Trials (1)
NCT03970746Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
Phase 1/2Help build intelligence for PDC*line Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.